Stock Update (NYSE:ABBV): AbbVie’s HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision

[PR Newswire] – NORTH CHICAGO, Ill., May 27, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European … Read more on this. AbbVie Inc. (ABBV) , currently valued at $100.34B, finished at $61.90. A quick look at the market, the company’s stock traded between $61.91 and $62.08 and has traded between $45.45 and $71.60 over the past year. ABBV shares are currently priced at 13.00x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 5.55x earnings multiple for the same period. The company pays shareholders $2.28 per share annually in dividends, yielding 3.76%. According to a consensus of 17 analysts, the earnings estimate of $1.20 per share would be $0.12 better than the year-ago quarter and a $0.04 sequential decrease. The full-year EPS estimate is $4.76 which would be a $0.47 improvement than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $6.20 Billion. If realized, that would be a 13.14% increase over the year-ago quarter. More recently, Societe Generale Initiated ABBV at Sell (Apr 6, 2016). Previously, Deutsche Bank Initiated ABBV at to Hold. The average price target for ABBV shares by the analysts covering it is $71.06, which is 14.80% above where the stock opened. See more in (NYSE:ABBV) Similar Articles: Company Update (NYSE:ABBV): AbbVie’s Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn’s Disease Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie’s HUMIRA® (adalimumab) receives Health Canada approval for the extension of the Polyarticular Juvenile Idiopathic Arthritis indication for patients between 2 and 4 years